Savara Reports Phase 3 Biomarker Gains for Rare Lung Disease
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported new Phase 3 clinical trial data showing its experimental therapy molgramostim improved lung function and reduced disease-associated biomarkers in patients with autoimmune …
Savara Reports Phase 3 Biomarker Gains for Rare Lung Disease Read More